Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
EXOZ · NASDAQ · Biological Products, (No Diagnostic Substances)
Exozymes (EXOZ) · oqro.io/stocks/EXOZ · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$3.83−0.17 (−4.25%)
Close of Nov 13, 2026, vs Nov 12 · end-of-day, not a live quote
Yes. Insiders of Exozymes (EXOZ) filed 5 open-market purchases in the last 90 days; the latest was filed on Sep 2, 2026.
Since 2024, Exozymes insiders reported 9 open-market purchases and 3 sales on Forms 4 and 5, with purchases in 3 different years, most recently 2026.
In the last 90 days, 1 insider of Exozymes (EXOZ) reported 1 open-market sale worth $19K in total on SEC Form 4. The largest seller by value was Damien Alan Perriman, with $19K. Many insider sales follow a plan set in advance or cover taxes on stock awards; the filing says what was sold, not the reason.
No trade in Exozymes (EXOZ) was disclosed by a member of Congress in the last 12 months.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−76.6% (−$12.57) from Nov 13, 2025 to Nov 13, 2026 · adjusted daily closes
Adjusted close went from $16.40 on Nov 13, 2025 to $3.83 on Nov 13, 2026 (−76.6%). Disclosed in this range: 7 insider trades, 1 pre-arranged insider sale, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Biological Products, (No Diagnostic Substances) company based in Monrovia, Ca.
Last 12 months
−76.7%
Market value
$35.5M
S&P 500 +12.3% over the same dates. Prices adjusted for splits and dividends.
Short interest: 18K shares sold short (0.2% of shares outstanding), +1.3% vs the previous count, 1.2 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Revenue
—
Free cash flow, last 12 months
−$7.14M
This quarter −$1.64M, a year earlier −$1.59M
Net debt
—
Debt —, cash $5.65M, at Jun 30, 2026
Net income, last 12 months
−$10.2M
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO.
Traded Aug 25 – Aug 26, 2026 · largest single transaction ~$1.9K
Aug 26, 2026~$1.8K · 251 sh @ $7.35
DetailsOfficial recordAug 26, 2026~$1.9K · 250 sh @ $7.60
DetailsOfficial recordAug 25, 2026~$1.9K · 250 sh @ $7.52
DetailsOfficial recordAug 25, 2026~$750 · 100 sh @ $7.50
DetailsOfficial recordPrices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Insiders of Exozymes reported 9 open-market purchases and 3 sales since 2024; purchases in 3 different years, most recently 2026.
| Year | Bought | Sold |
|---|---|---|
| 2026 | $6.4K5×5 trades | $35K3×3 trades |
| 2025 | $31K3×3 trades | — |
| 2024 | $22K1×1 trade | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Against the S&P 500 over the year
Since Nov 7, 2025, EXOZ is down 72.6% and the index fund is up 12.4%: 85 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much EXOZ moves
End-of-day prices. These figures describe the past year and say nothing about what comes next.